Our Pricing

How Long Does Wegovy Take to Suppress Appetite?

Published on: June 03, 2026

Understanding how long does Wegovy take to suppress appetite is one of the most common questions from patients starting semaglutide treatment. Most patients notice reduced hunger within the first 1-2 weeks of treatment, though the full appetite-suppressing effect builds gradually as your dose increases over the 16-week titration schedule. At Cured Pharmacy, our UK prescribers guide you through what to expect at each stage, with Wegovy available from £79.00 following your free online consultation.

The Science Behind Wegovy's Appetite Suppression

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural hormone glucagon-like peptide-1 produced in your intestines after eating [1]. This hormone signals to appetite centres in your hypothalamus that you're satisfied, while also slowing gastric emptying so food stays in your stomach longer.

Clinical pharmacology studies show semaglutide reaches steady-state concentrations in your bloodstream after 4-5 weeks of consistent weekly injections [1]. However, appetite suppression often begins much earlier because even initial doses activate GLP-1 receptors in the brain and digestive system.

The STEP 1 trial demonstrated that patients on semaglutide 2.4mg reported significantly reduced hunger scores within the first month of treatment, with progressive improvements throughout the 68-week study period [2]. This early onset distinguishes Wegovy from older weight loss medications that may take longer to produce noticeable effects.

Week-by-Week Timeline: When Does Wegovy Start Working?

The Wegovy dosing schedule follows a carefully designed titration protocol approved by the MHRA, starting at 0.25mg weekly and increasing every four weeks until reaching the maintenance dose of 2.4mg [3]. This gradual escalation minimises gastrointestinal side effects whilst allowing your body to adapt to semaglutide's effects.

During weeks 1-4 at the 0.25mg starter dose, approximately 60-70% of patients report noticing subtle changes in appetite and food cravings, though effects vary individually. You may find yourself satisfied with smaller portions or thinking about food less frequently between meals.

Weeks 5-8 at 0.5mg typically bring more pronounced appetite suppression for most patients. By week 8, clinical data from the STEP programme showed patients had already achieved meaningful weight reduction, averaging 5-7% body weight loss [2]. This correlates directly with the cumulative appetite-suppressing effects.

The full appetite-controlling effect of Wegovy becomes most apparent after reaching the 1.7mg or 2.4mg maintenance doses between weeks 13-20. At this stage, patients in clinical trials reported the most significant reductions in hunger, cravings, and overall food intake [2].

Individual Variation in Response Time

Whilst clinical trial data provides average timelines, individual response to Wegovy varies based on factors including your starting weight, metabolic rate, diet composition, and genetic differences in GLP-1 receptor sensitivity. Some patients notice appetite changes within 3-5 days of their first injection, whilst others require 3-4 weeks to perceive clear effects.

Your UK prescriber at Cured Pharmacy will monitor your progress throughout the titration schedule, adjusting the pace if you experience side effects or require additional time at lower doses before escalating.

How Long Does Wegovy Take to Suppress Appetite Compared to Alternatives?

When comparing appetite suppression timelines across licensed weight loss treatments in the UK, Wegovy's onset sits within the faster range. Saxenda (liraglutide), a daily GLP-1 injection, may produce appetite changes within 1-2 weeks similarly, but requires daily administration rather than weekly [4].

Oral medications like Mysimba work through different neurological pathways and typically require 4-8 weeks before patients notice consistent appetite reduction. Orlistat, which blocks fat absorption rather than suppressing appetite, produces weight loss through a completely different mechanism without directly affecting hunger signals.

Mounjaro (tirzepatide), the dual GIP/GLP-1 receptor agonist, follows a comparable timeline to Wegovy, with many patients reporting appetite suppression within the first 1-2 weeks. Head-to-head trials suggest tirzepatide may produce slightly greater weight loss overall, though both medications demonstrate robust appetite-controlling effects [5].

Maximising Wegovy's Appetite-Suppressing Effects

Whilst Wegovy works pharmacologically to reduce hunger, combining the medication with evidence-based lifestyle strategies enhances outcomes. The STEP trials required participants to follow a reduced-calorie diet and increase physical activity, contributing to the average 14.9% body weight reduction achieved over 68 weeks [2].

Protein intake significantly influences satiety independent of Wegovy's effects. Consuming 25-30g of protein at breakfast can complement semaglutide's appetite suppression, helping you feel satisfied longer. Staying well-hydrated also supports the medication's effects, as mild dehydration can sometimes be mistaken for hunger.

Timing your Wegovy injection consistently each week maintains stable semaglutide levels in your bloodstream, optimising continuous appetite control. Most patients find injecting on the same day weekly (such as every Sunday evening) helps establish a routine and ensures they don't miss doses.

Managing Early Side Effects

Nausea, the most common side effect during Wegovy's initial weeks, affects approximately 44% of patients but typically resolves as your body adjusts [3]. Eating smaller, more frequent meals and avoiding high-fat foods can minimise discomfort whilst your digestive system adapts to slower gastric emptying.

If side effects persist or significantly impact your quality of life, your UK prescriber may recommend staying at your current dose for an additional 4 weeks before escalating, or temporarily reducing the dose. This flexibility ensures you can continue treatment comfortably whilst still benefiting from appetite suppression.

What to Expect After Reaching Maintenance Dose

Once you've completed the titration schedule and reached the 2.4mg maintenance dose (typically by week 17-20), Wegovy's appetite-suppressing effects should feel consistent and predictable. Most patients describe a sustained reduction in hunger, smaller portion sizes feeling satisfying, and decreased preoccupation with food throughout the day.

Long-term data from the STEP 1 trial extension showed that appetite suppression and weight loss were maintained for up to 104 weeks in patients who continued Wegovy treatment [2]. This suggests semaglutide's effects don't diminish over time when used consistently, unlike some older weight loss medications that lose efficacy.

Your UK clinical team at Cured Pharmacy will schedule regular reviews to monitor your progress, assess whether the 2.4mg dose remains optimal, and ensure you're achieving your weight management goals. Some patients may find lower maintenance doses (such as 1.7mg) provide sufficient appetite control with fewer side effects.

Starting Wegovy Treatment at Cured Pharmacy

Wegovy is a prescription-only medication in the UK, requiring clinical assessment by a registered prescriber before it can be dispensed. At Cured Pharmacy, the process begins with a free online consultation taking under 3 minutes, reviewed by our UK-registered clinical team including superintendent pharmacist Tarun Kumar (GPhC 2233073).

We provide transparent upfront pricing with Wegovy available from £79.00, significantly lower than typical market rates, with no hidden fees or subscription requirements. Your medication is dispensed from our GPhC-registered pharmacy (9012511) and delivered in 100% discreet packaging directly to your address.

Our clinical team remains available throughout your treatment journey to answer questions about appetite changes, side effects, or dose adjustments. You'll receive clear guidance on injection technique, storage requirements, and what to expect at each stage of the titration schedule, ensuring you feel confident and supported from your first dose onwards.

Who Can Use Wegovy in the UK?

Wegovy is licensed by the MHRA for adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [3]. Your prescriber will verify eligibility during your consultation and ensure Wegovy is clinically appropriate based on your medical history.

Certain conditions contraindicate Wegovy use, including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disease. Full screening during your online assessment ensures safe, appropriate prescribing aligned with MHRA guidance.

Scientific References

1. Novo Nordisk. (2023). Wegovy (semaglutide) Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Public Assessment Report. GOV.UK. https://www.gov.uk/government/publications/wegovy-semaglutide [accessed 13 August 2026]
4. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
5. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.